TY - JOUR
T1 - A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments
AU - Greene, Yvonne M.
AU - Tariot, Pierre N.
AU - Wishart, Heather
AU - Cox, Christopher
AU - Holt, Connie J.
AU - Schwid, Steven
AU - Noviasky, John
PY - 2000/6/1
Y1 - 2000/6/1
N2 - Cognitive dysfunction occurs in up to 65% of patients with multiple sclerosis (MS), but there is no effective treatment for the symptoms. The authors conducted a 12-week, open-pilot study to assess the efficacy and tolerability of donepezil HCl administered in patients with MS and cognitive impairment. Seventeen patients at a long-term care facility with Mini-Mental State Examination scores of ≤25 received 5 mg of donepezil HCl for a 4-week period, followed by 8 weeks of 10 mg of donepezil HCl. Cognitive, neurologic, functional, and behavioral assessments were conducted at baseline and at 4 and 12 weeks. Statistically significant improvement was observed in several cognitive domains including attention, memory, and executive functioning, as well as different aspects of behavior. These data suggest that donepezil HCl merits further study as a potentially viable treatment option for patients with cognitive impairment associated with MS.
AB - Cognitive dysfunction occurs in up to 65% of patients with multiple sclerosis (MS), but there is no effective treatment for the symptoms. The authors conducted a 12-week, open-pilot study to assess the efficacy and tolerability of donepezil HCl administered in patients with MS and cognitive impairment. Seventeen patients at a long-term care facility with Mini-Mental State Examination scores of ≤25 received 5 mg of donepezil HCl for a 4-week period, followed by 8 weeks of 10 mg of donepezil HCl. Cognitive, neurologic, functional, and behavioral assessments were conducted at baseline and at 4 and 12 weeks. Statistically significant improvement was observed in several cognitive domains including attention, memory, and executive functioning, as well as different aspects of behavior. These data suggest that donepezil HCl merits further study as a potentially viable treatment option for patients with cognitive impairment associated with MS.
UR - http://www.scopus.com/inward/record.url?scp=0034072789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034072789&partnerID=8YFLogxK
U2 - 10.1097/00004714-200006000-00010
DO - 10.1097/00004714-200006000-00010
M3 - Article
C2 - 10831023
AN - SCOPUS:0034072789
SN - 0271-0749
VL - 20
SP - 350
EP - 356
JO - Journal of clinical psychopharmacology
JF - Journal of clinical psychopharmacology
IS - 3
ER -